Similar to MEK inhibitors (above) and KRASG12C inhibitors (below), tipifarnib treatment of HRAS-mutated cancer cells show adaptive reactivation RTK–WT RAS signaling and enhanced RAF/MEK/ERK pathway activation [91]. This evidence concerns the gene MAP2K7 and cancer.